A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
Evan Soltas and Jonathan Gruber have published a paper titled, “How Costly Is Permitting in Housing Development?”. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results